Reason for request
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
F3UrbngbrATpYk6x
Listen
